Table 5 Timing of chemotherapy of MPM patients between PS and non-PS groups
From: Risk factors and prognosis of malignant peritoneal mesothelioma with paraneoplastic syndrome
Variables | Non-PS group (n = 86) | PS group (n = 60) | P value |
|---|---|---|---|
Preoperative intravenous chemotherapy, n (%) | 0.342 | ||
No | 47 (54.7) | 28 (46.7) | |
Yes | 39 (45.3) | 32 (53.3) | |
Preoperative intraperitoneal chemotherapy, n (%) | 0.606 | ||
No | 73 (84.9) | 49 (81.7) | |
Yes | 13 (15.1) | 11 (18.3) | |
Postoperative intravenous chemotherapy, n (%) | 0.003 | ||
No | 1 (1.2) | 1 (1.7) | |
Yes | 72 (83.7) | 33 (55.0) | |
NA | 11 (12.8) | 18 (30.0) | |
Death | 2 (2.3) | 8 (13.3) | |
Postoperative intraperitoneal chemotherapy, n (%) | 0.010 | ||
No | 26 (30.2) | 13 (21.7) | |
Yes | 47 (54.7) | 21 (35.0) | |
NA | 11 (12.8) | 18 (30.0) | |
Death | 2 (2.3) | 8 (13.3) | |